Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, February 21, 2017
Lonza now offers cryopreserved lung fibroblasts isolated from donors diagnosed with Idiopathic Pulmonary Fibrosis (IPF) for use in research into this potentially fatal condition.
read more
Wednesday, March 27, 2019
Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs.
read more
Lonza announced the establishment of a Center of Excellence for Dry Powder Inhaler drug product development at its OR site.
read more
Thursday, February 19, 2026
Lonza announced that it has strengthened its Advanced Synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates.
read more
Lonza and Integral Molecular announced a strategy to offer complementary expertise to their respective customers to better assess the risks of off-target binding of biologic drug candidates.
read more
Friday, February 17, 2023
Lonza has completed its planned expansion of the bioconjugation facility in Visp (CH). The expansion includes two new manufacturing suites and supporting infrastructure to accommodate a wider range of customers, including companies entering clinical ...
read more
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.
read more
Wednesday, March 29, 2023
The new line will support customers with a range of drug product manufacturing needs for both clinical and commercial supply.
read more
Lonza announced it has completed the acquisition of Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion.
read more
Tuesday, January 17, 2023
Lonza announced two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering.
read more
Tuesday, February 26, 2019
Lonza announced Richard Ridinger, CEO, has decided to retire from the company after seven years.
read more
Friday, November 06, 2020
Lonza inaugurated the first of two manufacturing suites for ADC drug-linker manufacturing at the Visp (CH) site.
read more
Monday, November 06, 2017
Lonza Walkersville announced its new offering of Silensomes Human Liver Microsomes products – pooled human liver microsomes for in vitro cytochrome P450 phenotyping.
read more
Tuesday, November 17, 2020
Lonza has announced that it now provides a large selection of high-resolution HLA-typed primary cells spanning all major cell and tissue types.
read more
Lonza has announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US).
read more